Dr. Jorge Duconge

A major goal of my current research agenda is to conduct multi-omics studies (e.g., pharmacogenomics, proteomics, eQTL profiling, genetics of gene expression, physiogenomics) in order to advance the implementation of the new paradigm of precision medicine in the admixed Caribbean Hispanic population. Such translational studies pursue the interest of advance current healthcare standards in this population, and the population at large, as well as a reduction of disparities of health. As part of these efforts, my lab seeks to implement strategies for the identification and characterization of novel biomarkers in high-risk Puerto Rican patients to predict major adverse events and therapeutic failure. In addition, we also work on developing PK/PD models and pharmacometrics to characterize novel compounds and delivery systems and predict optimal dosing schemes (e.g., dual Rac/Cdc42 Inhibitor MBQ-167 and EHop-16; high-doses of IV vitamin C; pegylated rhuEPO; warfarin, etc.). I am a full-time faculty member (Professor; four-times Teacher of the Year award) at the University of Puerto Rico, School of Pharmacy (UPR-SoP), with an excellent record of productive research in clinical pharmacology, pharmacokinetics, and pharmacogenomics. I have a broad background in pharmacokinetics and, over the last 10+ years, I have been well trained in the evolving field of pharmacogenomics and precision medicine.